The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
Open accessPublished version of a preprint
Abstract
SARS-CoV-2 antibodies persist: As the number of daily COVID-19 cases continues to mount worldwide, the nature of the humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains uncertain. Wajnberg et al. used a cohort of more than 30,000 infected individuals with mild to moderate COVID-19 symptoms to determine the robustness and longevity of the anti–SARS-CoV-2 antibody response. They found that neutralizing antibody titers against the SARS-CoV-2 spike protein persisted for at least 5 months after infection. Although continued monitoring of this cohort will be needed to confirm the longevity and potency of this response, these preliminary results suggest that the chance of reinfection may be lower than is currently feared. Science , this issue p. 1227
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“data so far indicate that T cell memory, B cell memory, and antibodies are all likely to persist for years in most individuals infected by SARS-CoV-2 (Dan et al., 2021; Gaebler et al., 2020; Wajnberg et al., 2020; Zuo et al., 2020a).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Wajnberg et al., 2020
Experimental — accuracy not yet measuredIn the citing paper
“However, given the relatively small size of some of these cohorts and the lack of systematic SARS-CoV-2 molecular testing, the true population effect remains unknown.”
In the citing paper
“More than 90% of individuals infected with SARS-CoV-2 develop antibodies about 1 week after symptom onset, persisting for at least 3 months.”
In the citing paper
“A few studies to date have reported that individuals with SARS-CoV-2 antibodies are at lower risk of clinical reinfection than are antibody-negative individuals.”
In the citing paper
“Although the exact length of immunity conferred by natural infection is still unknown, titres of neutralising antibodies against the SARS-CoV-2 spike protein were detectable for at least 5 months after primary infection.”
In the citing paper
“SARS-CoV-2 infection can induce the production of neutralizing antibodies, and these antibodies are believed to contribute to protection from reinfection (Rodda et al., 2020; Wajnberg et al., 2020).”
From SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies (2021) · cites this paper as Wajnberg et al., 2020
In the citing paper
“However, it should also be noted that circulating SARS-CoV-2 neutralizing antibody titers are relatively low in a substantial fraction of recovered COVID-19 cases (Dan et al., 2021; Robbiani et al., 2020; Wajnberg et al., 2020), indicating that either the neutralizing antibody potency or the serum concentration is suboptimal in this subset.”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Wajnberg et al., 2020
In the citing paper
“circulating SARS-CoV-2 IgG titers are well maintained for 3–4 months (Gudbjartsson et al., 2020; Wajnberg et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Wajnberg et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769
Self-citationCorrelates of protection induced by vaccination
Plotkin, S. A. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00131-10 · Cited by 1,745
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
Shi, R., Shan, C., Duan, X., Chen, Z., Liu, P., Song, J., Song, T., Bi, X., Han, C., Wu, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2381-y · Cited by 1,286
SARS-CoV-2 Vaccines: Status Report
Amanat, F., & Krammer, F. (2020) · Immunity · doi:10.1016/j.immuni.2020.03.007 · Cited by 1,120
Self-citationHuang, A. T., Garcia-Carreras, B., Hitchings, M. D. T., Yang, B., Katzelnick, L. C., Rattigan, S. M., Borgert, B. A., Moreno, C. A., Solomon, B. D., Trimmer-Smith, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18450-4 · Cited by 1,026
DNA vaccine protection against SARS-CoV-2 in rhesus macaques
Yu, J., Tostanoski, L. H., Peter, L., Mercado, N. B., McMahan, K., Mahrokhian, S. H., Nkolola, J. P., Liu, J., Li, Z., Chandrashekar, A., et al. (2020) · Science · doi:10.1126/science.abc6284 · Cited by 997
Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development
Imai, M., Iwatsuki‐Horimoto, K., Hatta, M., Loeber, S. J., Halfmann, P., Nakajima, N., Watanabe, T., Ujie, M., Takahashi, K., Ito, M., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2009799117 · Cited by 994
Self-citationSARS-CoV-2 infection protects against rechallenge in rhesus macaques
Chandrashekar, A., Liu, J., Martinot, A. J., McMahan, K., Mercado, N. B., Peter, L., Tostanoski, L. H., Yu, J., Maliga, Z., Nekorchuk, M., et al. (2020) · Science · doi:10.1126/science.abc4776 · Cited by 816
Stadlbauer, D., Amanat, F., Chromikova, V., Jiang, K., Strohmeier, S., Arunkumar, G. A., Tan, J., Bhavsar, D., Capuano, C., Roubidoux, E. K., et al. (2020) · Current Protocols in Microbiology · doi:10.1002/cpmc.100 · Cited by 635
Self-citationConvalescent plasma treatment of severe COVID-19: a propensity score–matched control study
Liu, S. T. H., Lin, H.-M., Baine, I. L., Wajnberg, A., Gumprecht, J. P., Rahman, F., Rodriguez, D., Tandon, P., Bassily‐Marcus, A., Bander, J. A., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1088-9 · Cited by 498
Self-citationPrimary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques
Deng, W., Bao, L., Liu, J., Xiao, C., Liu, J., Xue, J., Lv, Q., Qi, F., Gao, H., Yu, P., et al. (2020) · Science · doi:10.1126/science.abc5343 · Cited by 440
Serology assays to manage COVID-19
Krammer, F., & Simon, V. R. (2020) · Science · doi:10.1126/science.abc1227 · Cited by 323
Self-citationDeming, D., Sheahan, T. P., Heise, M. T., Yount, B. L., Davis, N., Sims, A. M., Suthar, M. S., Harkema, J. R., Whitmore, A. C., Pickles, R. J., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030525 · Cited by 273
Wajnberg, A., Mansour, M., Leven, E. A., Bouvier, N. M., Patel, G., Firpo‐Betancourt, A., Mendu, R., Jhang, J. S., Arinsburg, S. A., Gitman, M., et al. (2020) · The Lancet Microbe · doi:10.1016/s2666-5247(20)30120-8 · Cited by 229
Self-citationA Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus
Gunn, B. M., Yu, W., Karim, M. M., Brannan, J. M., Herbert, A. S., Wec, A. Z., Halfmann, P., Fusco, M. L., Schendel, S. L., Gangavarapu, K., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.07.009 · Cited by 222
An In Vitro Microneutralization Assay for SARS‐CoV‐2 Serology and Drug Screening
Amanat, F., White, K. M., Miorin, L., Strohmeier, S., McMahon, M., Meade, P. S., Liu, W., Albrecht, R. A., Simon, V. R., Martínez‐Sobrido, L., et al. (2020) · Current Protocols in Microbiology · doi:10.1002/cpmc.108 · Cited by 171
Self-citationRepeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City
Stadlbauer, D., Tan, J., Jiang, K., Hernandez, M. M., Fabre, S., Amanat, F., Teo, C., Arunkumar, G. A., McMahon, M., Capuano, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2912-6 · Cited by 168
Self-citationAntibody-mediated protection against Ebola virus
Saphire, E. O., Schendel, S. L., Gunn, B. M., Milligan, J. C., & Alter, G. (2018) · Nature Immunology · doi:10.1038/s41590-018-0233-9 · Cited by 136
High neutralizing antibody titer in intensive care unit patients with COVID-19
Liu, L., To, K. K., Chan, K., Wong, M. Y.-C., Zhou, R., Kwan, K., Fong, C. H.-Y., Chen, L., Choi, C. Y.-K., Lu, L., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1791738 · Cited by 135
Krammer, F., Weir, J. P., Engelhardt, O. G., Katz, J. M., & Cox, R. J. (2019) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12706 · Cited by 83
Self-citationAsymptomatic Seroconversion of Immunoglobulins to SARS-CoV-2 in a Pediatric Dialysis Unit
Hains, D. S., Schwaderer, A. L., Carroll, A. E., Starr, M. C., Wilson, A. C., Amanat, F., & Krammer, F. (2020) · JAMA · doi:10.1001/jama.2020.8438 · Cited by 70
Self-citationDingens, A. S., Crawford, K. H. D., Adler, A., Steele, S. L., Lacombe, K., Eguia, R. T., Amanat, F., Walls, A. C., Wolf, C. R., Murphy, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18178-1 · Cited by 69
Self-citationSeroconversion of a city: Longitudinal monitoring of SARS-CoV-2 seroprevalence in New York CityPreprint
Stadlbauer, D., Tan, J., Jiang, K.-J., Hernandez, M., Fabre, S., Amanat, F., Teo, C., Arunkumar, G. A., McMahon, M., Jhang, J., et al. (2020) · medRxiv · doi:10.1101/2020.06.28.20142190 · Cited by 48
Self-citationThe Role of Fc Gamma Receptors in Broad Protection against Influenza Viruses
Thulin, N. K., & Wang, T. T. (2018) · Vaccines · doi:10.3390/vaccines6030036 · Cited by 37
Cited by
Sorted by citations
RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
Huang, C., Huang, L., Wang, Y., Li, X., Ren, L., Gu, X., Kang, L., Guo, L., Liu, M., Zhou, X., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32656-8 · Cited by 4,084
RetractedImmunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656
“1016/S0140-6736(20)30566-3; pmid: 32171076”
BackgroundInfluentialSelf-citationSARS-CoV-2 vaccines in development
Krammer, F. (2020) · Nature · doi:10.1038/s41586-020-2798-3 · Cited by 2,098
Self-citationAdaptive immunity to SARS-CoV-2 and COVID-19
Sette, A., & Crotty, S. (2021) · Cell · doi:10.1016/j.cell.2021.01.007 · Cited by 1,860
Rydyznski Moderbacher, C., Ramirez, S. I., Dan, J. M., Grifoni, A., Hastie, K. M., Weiskopf, D., Belanger, S., Abbott, R. K., Kim, C., Choi, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.038 · Cited by 1,790
Metadata
- Authors
- Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., Stadlbauer, D., Stone, K., Strohmeier, S., Simon, V., Aberg, J., Reich, D. L., Krammer, F., & Cordon-Cardo, C.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- Clinical Microbiology Laboratory, Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
- Corresponding author
- Wajnberg, Ania
- Krammer, Florian
- ORCID
- Venue
- Science
- Published
- 2020-12-04
- Volume
- 370
- Issue
- 6521
- Pages
- 1227-1230
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7810037
- OpenAlex
- W3094968263
- Cited by
- 1,195
- References
- 28
- Citations by year
- 2026: 16 · 2025: 46 · 2024: 50 · 2023: 117 · 2022: 280 · 2021: 594 · 2020: 92
- FWCI
- 35.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- medRxiv (acceptedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ImmPort
- Funders
- National Institute of Allergy and Infectious Diseases (HHSN272201400008C, 75N93019C00051)
- JPB Foundation
- Open Philanthropy Project (#2020-215611)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
- Keywords
- SARS-CoV-2, COVID-19 pandemic, neutralizing antibodies, IgG, spike protein, antibody persistence, antibody titers, seroconversion, mild to moderate COVID-19
- MeSH terms
- COVID-19, SARS-CoV-2, Antibodies, Viral, Enzyme-Linked Immunosorbent Assay, Humans, Immunoglobulin G, Neutralization Tests, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
